BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» FDA Rejects InterMune Lung Drug; Seeks More Trial Data
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA Rejects InterMune Lung Drug; Seeks More Trial Data
May 5, 2010
By
Donna Young
No Comments
WASHINGTON - InterMune Inc. failed to win FDA approval of Esbriet (pirfenidone) as a treatment for a fatal lung disease, known as idiopathic pulmonary fibrosis (IPF), despite the strong backing of an agency panel of experts.
BioWorld